Lynparza (olaparib) Letter of Medical Necessity
Lynparza (olaparib) is the most broadly indicated PARP inhibitor, spanning ovarian, breast, pancreatic, and prostate cancer. Every indication is biomarker-gated, so payers almost always deny submissions that arrive without the companion diagnostic report. Attaching the test result and mapping the request to the exact labeled line of therapy resolves most PA issues.
FDA-Approved Indications
- ● BRCA-mutated or HRD-positive advanced ovarian cancer (maintenance)
- ● germline BRCA-mutated HER2-negative breast cancer (metastatic and high-risk early)
- ● germline BRCA-mutated metastatic pancreatic cancer (maintenance)
- ● HRR gene-mutated metastatic castration-resistant prostate cancer
Why Lynparza Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. BRCA, HRD, or HRR companion diagnostic result not submitted
- 2. Response to prior platinum-based chemotherapy not documented (ovarian and pancreatic maintenance)
- 3. Line of therapy or prior treatment history does not match the labeled indication
- 4. Prior PARP inhibitor use not addressed
- 5. Combination partner (bevacizumab or abiraterone) not specified
- 6. Oral oncology specialty pharmacy requirement not met
What to Include in a Lynparza Letter of Medical Necessity
Attach the germline or tumor BRCA / HRD / HRR test report, state the cancer type, stage, and line of therapy, document response to prior platinum chemotherapy where required for maintenance, list prior systemic therapies with dates, specify any combination partner, and cite the NCCN category of evidence for the requested use.
Key clinical evidence to cite:
- ✓ SOLO-1 and SOLO-2 (ovarian maintenance, BRCAm) and PAOLA-1 (with bevacizumab, HRD-positive)
- ✓ OlympiAD (metastatic gBRCAm breast) and OlympiA (adjuvant high-risk early breast, overall survival benefit)
- ✓ POLO (gBRCAm metastatic pancreatic maintenance)
- ✓ PROfound and PROpel (metastatic castration-resistant prostate cancer)
Relevant guidelines:
- 📖 NCCN Ovarian Cancer Guidelines
- 📖 NCCN Breast Cancer Guidelines
- 📖 NCCN Pancreatic Adenocarcinoma Guidelines
- 📖 NCCN Prostate Cancer Guidelines
Lynparza Prior Authorization Criteria
Standard criteria across major US payers for Lynparza. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Response to prior platinum-based chemotherapy not documented (ovarian and pancreatic maintenance)
- → Line of therapy or prior treatment history does not match the labeled indication
- → Prior PARP inhibitor use not addressed
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Lynparza
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Lynparza Prior Authorization FAQ
Why was my Lynparza prior authorization denied?
The most common denial reasons for Lynparza are: BRCA, HRD, or HRR companion diagnostic result not submitted; Response to prior platinum-based chemotherapy not documented (ovarian and pancreatic maintenance); Line of therapy or prior treatment history does not match the labeled indication; Prior PARP inhibitor use not addressed; Combination partner (bevacizumab or abiraterone) not specified; Oral oncology specialty pharmacy requirement not met.
What should a Lynparza Letter of Medical Necessity include?
Attach the germline or tumor BRCA / HRD / HRR test report, state the cancer type, stage, and line of therapy, document response to prior platinum chemotherapy where required for maintenance, list prior systemic therapies with dates, specify any combination partner, and cite the NCCN category of evidence for the requested use.
Which payers cover Lynparza?
Lynparza is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.